Monogram Technologies' Management Invests $1 Million in Company Stock, Signaling Confidence in AI-Driven Orthopedic Surgery Solutions

Management Demonstrates Confidence Through Stock Purchases

Monogram Technologies Inc. (NASDAQ:MGRM), an AI-driven robotics company focused on improving human health, has announced that its management and related parties have completed open market purchases of MGRM common stock totaling approximately $1 million. The purchases, including those made by Chief Financial Officer Noel Knape, reflect the senior management team's high confidence in the company's strategy and its potential to create long-term shareholder value 1

1

2

Company Overview and Technology Focus

Monogram Technologies is developing a product solution architecture that combines 3D printing, advanced machine vision, AI, and next-generation robotics to enable patient-optimized orthopedic implants at scale. The company's initial focus is on orthopedic surgery, particularly knee replacements 1

1

2

Key Products and Innovations

The company's flagship product, the mBôs precision robotic surgical system, is designed to autonomously execute optimized paths for high-precision insertion of FDA-cleared mPress press-fit implants. This system aims to provide well-balanced, better-fitting, and bone-sparing knee replacements 1

1

2

Monogram's technology stack includes:

1. mBôs precision robotic surgical assistants
2. mVision navigation system
3. mPress press-fit implants (FDA-cleared)

The company believes that combining AI and novel navigation methods will enable more personalized knee implants, resulting in improved outcomes for patients 1

1

2

Regulatory Status and Future Plans

Monogram has already obtained FDA clearance for its mPress implants and has applied for 510(k) clearance for its robotic products. The company is required to secure FDA clearance before marketing these products, though the timing and ability to obtain such clearances cannot be guaranteed 1

1

2

Market Potential and Expansion

While initially focusing on knee replacements, Monogram anticipates potential applications for its mBôs precision robot and mVision navigation in other clinical and commercial areas. The company plans to produce and market robotic surgical equipment, related software, orthopedic implants, tissue ablation tools, navigation consumables, and other instrumentation necessary for reconstructive joint replacement procedures 1

1

2

Related Stories

Monogram Technologies Receives FDA Response for mBôs TKA System and Closes $13 Million Public Offering

Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024, Highlighting AI-Driven Robotic Surgery Advancements

Monogram Technologies to Showcase AI-Driven Robotic Surgical System at LD Micro Main Event XVII Conference

MeiraGTx and Hologen AI Form $430 Million Joint Venture to Accelerate AI-Driven Gene Therapy for Parkinson's Disease

Financial Outlook and Recent Developments

CEO Ben Sexson expressed optimism about the company's ability to reach key milestones in the coming months, citing recent funding secured from an offering. The management's decision to purchase shares in the open market is seen as a strong vote of confidence in the company's future prospects 1

1

2

Cautionary Note on Forward-Looking Statements

As with many innovative companies, Monogram Technologies' press release includes forward-looking statements. These statements are subject to various risks and uncertainties, and actual results may differ materially from projections. Investors are advised to consider these factors when evaluating the company's potential 1

1

2